New PET tracers aim to spot tau tangles in rare brain disease

NCT ID NCT07348276

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, designed to light up tau protein buildup in the brain during a PET scan. Tau buildup is linked to Progressive Supranuclear Palsy (PSP), a rare movement and thinking disorder. The trial includes up to 24 adults (healthy volunteers and people with PSP) to check safety, radiation exposure, and how well the drugs show tau in the brain. Better imaging could help diagnose PSP earlier and track disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[18F]ABBV-964i and [18F]ABBV-965i (imaging drugs used in PET scans)
What this could lead to
If successful, these imaging drugs could help doctors see tau buildup in the brain, leading to earlier and more accurate diagnosis of PSP and better tools for tracking the disease.
What could go wrong
This is a very early, small study (24 people) focused on safety and imaging quality, not treatment. The drugs may not work as hoped, and results may not apply to larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Invicro (dba Perceptive)

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.